Cancer Chemoprevention Using Pharmacolgical, Natural, or Dietary Agents

Chemoprevention of cancer refers to the prevention of invasive cancer It is defined as suppressing the occurrence of. Conservation strategies Although statistically observed in animal models, comprehensive protection against carcinogen-induced tumor progression is achieved by administering chemopreventive agents before or concurrent with carcinogen exposure. [49].

Chemopreventive chemoprophylaxis refers to the use of drugs to reduce the risk of cancer. The US Food and Drug Administration (FDA) has approved two chemopreventive drugs (tamoxifen and raloxifene) to reduce the risk of breast cancer among high-risk women, but these drugs are harmful BRCA1 or BRCA2 mutations It is raising. The role of women is not so. But, it is very clear. However, for women who do not choose surgery or who can not undergo surgery, these medications may be an option. Three studies show that tamoxifen reduces the risk of breast cancer in women with adverse mutations in BRCA 2 (24) and the risk of breast cancer diagnosed previously as a carrier of mutations in BRCA1 and BRCA2 There is a possibility that it will be useful. Breast cancer (25, 26). This study has not specifically studied the effectiveness of raloxifene in BRCA1 and BRCA2 mutation carriers.

Chemoprevention of cancer is defined as the use of natural products to reduce risk and to stop or reverse the developmental process of cancer. Resveratrol is one of them. It is a well-known terpenoid, a grape with the property of preventing cancer. Lee et al. Synthesized derivatives of terpenoids and tested long-term experiments using 3,4,5-trimethoxy-4-bromo-cis-styrene (BCS), indicating potential growth inhibition. Function BCS then conducted a series of surveys to determine whether it is a potential cancer chemopreventive drug. BCS appears to be an excellent growth inhibitor and apoptosis inducer in A549 lung cancer cells

The results of this study may lead to two conclusions that may help to optimize curcumin clinical trials as a cancer chemopreventive drug. (A) The bioavailability of curcumin in blood and tissues is significantly affected by po. Management; (b) colonic mucosa and liver are pharmacological targets of dietary curcumin. The initial conclusion was based on differences in the plasma and tissue levels of curcumin and its conjugates observed after the two dosing modes. Dietary curcumin causes a drug concentration of 0.3 to 1.8 μmol / g in the colonic mucosa, but the plasma level is close to the detection limit. Curcumin is provided, for example, suspended in a solvent mixture. The level of drug provided in the plasma is 3-6 times higher than the level after meal administration. The curcumin metabolite can be detected only in, for example, plasma. Instead, the result is colonic mucosa level after curcumin.

Effect of dietary curcumin on glutathione S-transferase and malondialdehyde-DNA adduct of rat liver and colonic mucosa